Three cancer drugs separately earned FDA approval: The KRAS inhibitor sotorasib (Lumakras; Amgen) was approved for use with the EGFR inhibitor panitumumab (Vectibix; Amgen) to treat patients with ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

NCI Director W. Kimryn Rathmell, MD, PhD, announced today that she will step down effective Monday, January 20, the same day Donald Trump will be inaugurated as president. Rathmell, who had previously ...

3Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. *Corresponding Author: David A. Reardon, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.

1Northwestern University, Chicago, Illinois.

1Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

1Division of Solid Tumor Oncology, Memorial Sloan Kettering, New York, New York. *Corresponding Author: Luis A. Diaz Jr, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. E ...

1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Although it has risen from 7% over the past decade, the relative 5-year survival rate for pancreatic cancer is 13%, the same rate as reported last year, according to the just released American Cancer ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

1Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain. 2Department of ...